Helix BioPharma Corp. (TSX:HBP, OTC PINK:HBPCD, FRANKFURT:HBP0), a clinical-stage oncology company focused on hard-to-treat cancers, announced today that its board of directors has granted 1,297,000 incentive stock options to directors, officers, employees and consultants under its equity compensation plan. Each option is exercisable to acquire one common share at an exercise price of $1.63 per share for a period of five years from the date of grant, subject to vesting provisions.
Concurrently, the company announced the cancellation of 2,200,000 incentive stock options previously granted on July 19, 2024, to a director. The cancelled options had an exercise price of $1.10 per share and were set to expire on July 19, 2029. The director did not receive any stock options in the current grant.
The grant and cancellation of stock options are routine corporate actions that align with Helix's equity compensation strategy. However, they come at a pivotal time for the company as it advances its pipeline of oncology therapies. Helix's lead candidate, Tumor Defense Breaker™ L-DOS47, is a clinical-stage antibody-enzyme conjugate designed to prime CEACAM6-expressing tumors for increased sensitivity to therapy. It has completed Phase Ib studies in non-small cell lung cancer (NSCLC). The company is also developing next-generation bi-specific antibody-drug conjugates (ADCs) based on the same CEACAM6-targeting foundation, currently in discovery.
Beyond L-DOS47, Helix is advancing two pre-IND candidates: LEUMUNA™, an oral immune checkpoint modulator aimed at achieving durable remission in post-transplant leukemia relapse, and GEMCEDA™, a first-in-class oral gemcitabine prodrug with bioavailability comparable to intravenous administration, designed to expand treatment options for advanced cancers.
These developments are important for investors and the oncology community because they signal Helix's continued commitment to its pipeline despite the financial adjustments represented by the option changes. The cancellation of a large block of options held by a director may indicate a recalibration of executive compensation or a strategic move to reduce potential dilution. For the company, maintaining a motivated team through stock options is crucial as it navigates clinical development and seeks to bring novel therapies to market. For the industry, Helix's focus on hard-to-treat cancers, such as NSCLC and post-transplant leukemia relapse, addresses significant unmet medical needs. If successful, L-DOS47 and its successors could improve outcomes for patients with CEACAM6-expressing tumors, while GEMCEDA could offer an oral alternative to intravenous gemcitabine, potentially improving patient convenience and quality of life.
The company's stock is listed on the TSX, OTC PINK, and Frankfurt Stock Exchange. More information is available on its website at https://www.helixbiopharma.com/.
Forward-looking statements in the announcement involve risks and uncertainties, and actual results may differ materially. Details are available in the company's filings on SEDAR+ at www.sedarplus.ca.
